浙江钱江生物化学股份有限公司 会计师事务所选聘制度 （经 2024 年 10 月 28 日十届十次董事会审议通过） 第一章 总 则 第一条 为规范浙江钱江生物化学股份有限公司（以下简称"公司"）选聘 会计师事务所相关行为，切实维护公司及股东利益，提高财务信息和审计工作 质量，根据《中华人民共和国公司法》《中华人民共和国证券法》《上海证券 交易所股票上市规则》《国有企业、上市公司选聘会计师事务所管理办法》 《浙江钱江生物化学股份有限公司章程》（以下简称"《公司章程》"）及相 关法律、法规，制定本制度。 第二条 本制度所称选聘会计师事务所，是指公司根据相关法律、法规要求， 聘任会计师事务所对公司会计报表发表审计意见、出具审计报告的行为。公司选 聘会计师事务所从事除财务会计报告审计之外的其他法定审计业务的，公司可参 照本制度执行。 第四条 公司控股股东、实际控制人不得在公司董事会、股东大会审议前， 向公司指定会计师事务所，也不得干预审计委员会独立履行选聘职责。 第二章 会计师事务所执业质量要求 第三条 公司选聘或解聘会计师事务所，应当经董事会审计委员会（以下简 称"审计委员会"）审议同意后，提交董事会审议，并由股东 ...

投资者可于 2024 年 10 月 30 日(星期三) 至 11 月 05 日(星期 二)16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或 通过公司邮箱 qjbioch@600796.com 进行提问。公司将在说明会上对 投资者普遍关注的问题进行回答。 浙江钱江生物化学股份有限公司（以下简称"公司"）已于 2024 年 10 月 29 日发布公司 2024 年第三季度报告，为便于广大投资者更 全面深入地了解公司 2024 年第三季度经营成果、财务状况，公司计 划于 2024 年 11 月 06 日 上午 10:00-11:00 举行 2024 年第三季度业 绩说明会，就投资者关心的问题进行交流。 证券代码：600796 证券简称：钱江生化 公告编号：临 2024-041 浙江钱江生物化学股份有限公司 关于召开 2024 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 会议召 ...

股票简称：钱江生化 证券代码：600796 编号：临 2024-040 浙江钱江生物化学股份有限公司 十届十次监事会决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示: 一、 监事会会议召开情况 浙江钱江生物化学股份有限公司监事会 1 监事是否未能出席（亲自出席或委托出席）本次监事会：无。 有监事是否对本次监事会某项议案投反对/弃权票：无。 本次监事会是否有某项议案未获通过：无。 表决结果：3 票同意、0 票反对、0 票弃权。 本次会议表决由监事朱炳其先生和朱霞芳女士进行计票和监票。 特此公告。 浙江钱江生物化学股份有限公司（以下简称"公司"）十届十次监事会会议 于2024年10月28日，以现场表决方式在公司会议室召开。会议通知于2024年10 月18日以书面及电子邮件方式发出。会议应到监事三名，实到监事三名，监事会 主席余强主持了会议，本次会议的召开符合《公司法》及《公司章程》的规定。 二、监事会会议审议情况 监事会全体人员对《公司 2024 年第三季度报告》进行了认真审议，并发表 以下意见： 报告 ...

Financial Performance - The company's operating revenue for Q3 2024 was ¥437,919,809.91, representing a decrease of 5.00% compared to the same period last year[2]. - The net profit attributable to shareholders for Q3 2024 was ¥46,606,685.82, down 15.47% year-on-year[2]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥45,110,859.52, a decrease of 14.34% compared to the previous year[2]. - Basic and diluted earnings per share for Q3 2024 were both ¥0.05, down 16.67% from the same period last year[4]. - Total operating revenue for the first three quarters of 2024 was CNY 1,300,581,051.60, a decrease of 2.3% compared to CNY 1,328,333,633.25 in the same period of 2023[15]. - Net profit for the first three quarters of 2024 was CNY 107,298,354.12, compared to CNY 127,157,866.81 in the same period last year, indicating a decline of 15.6%[16]. - Earnings per share for the third quarter of 2024 was CNY 0.15, unchanged from the previous quarter but down from CNY 0.16 in the same quarter of 2023[17]. Cash Flow - The net cash flow from operating activities for the year-to-date was ¥18,709,249.34, reflecting a significant decline of 83.94%[2][7]. - In the first three quarters of 2024, the cash inflow from operating activities totaled ¥1,237,298,927.50, a decrease of 11% compared to ¥1,391,359,040.03 in the same period of 2023[19]. - The net cash flow from operating activities for the first three quarters of 2024 was ¥18,709,249.34, significantly down from ¥116,517,573.71 in 2023, indicating a decline of approximately 84%[19]. - The cash outflow for operating activities was ¥1,218,589,678.16 in the first three quarters of 2024, compared to ¥1,274,841,466.32 in 2023, reflecting a reduction of approximately 4.4%[19]. - The company reported a cash inflow from other operating activities of ¥111,687,737.91 in 2023, which was significantly higher than the cash inflow of ¥18,713,506.79 in 2024, indicating a decline of about 83%[19]. Assets and Liabilities - Total assets at the end of the reporting period were ¥7,493,416,607.84, an increase of 9.05% from the end of the previous year[4]. - The company's total assets reached approximately RMB 7.49 billion, up from RMB 6.87 billion at the end of 2023[12]. - The company's total liabilities increased to CNY 3,978,434,054.50 in Q3 2024, up from CNY 3,374,593,671.20 in Q3 2023, indicating a rise in financial leverage[14]. - Long-term borrowings rose to CNY 1,050,116,149.44 in Q3 2024, compared to CNY 974,498,112.43 in the same period last year, reflecting increased financing activities[14]. - Non-current assets total approximately RMB 4.99 billion, compared to RMB 4.54 billion at the end of 2023[12]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period is 25,953, with the top ten shareholders holding a combined 76.39% of shares[8]. - The largest shareholder, Haining Water Investment Group, holds 389,756,986 shares, representing 44.98% of the total[8]. - Shareholders' equity attributable to the parent company was ¥3,241,908,156.44, up 3.31% compared to the end of the previous year[4]. - The company's total equity reached CNY 3,514,982,553.34 in Q3 2024, slightly up from CNY 3,496,729,417.93 in Q3 2023, showing stability in shareholder value[14]. Investment and Expenses - Research and development expenses for the first three quarters of 2024 were CNY 17,701,048.30, down from CNY 22,226,502.88 in the same period of 2023, indicating a potential shift in R&D focus[15]. - The company reported a decrease in financial expenses to CNY 52,711,996.35 in 2024 from CNY 60,690,750.44 in 2023, suggesting improved cost management[15]. - The cash outflow for investing activities in the first three quarters of 2024 was ¥613,034,229.48, compared to ¥136,878,157.16 in 2023, reflecting a substantial increase in investment expenditures[19]. - The cash inflow from investment activities was ¥38,797,882.39 in the first three quarters of 2024, down from ¥50,372,097.41 in 2023, showing a decrease of about 23%[19]. Government Support - Non-recurring gains and losses for the current period included government subsidies amounting to ¥230,484.83[5].

证券代码：600796 股票简称：钱江生化 编号：临 2024—038 浙江钱江生物化学股份有限公司 关于持股 5%以上股东所持部分公司股份被司法冻结 的进展暨司法拍卖完成过户的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： ● 浙江钱江生物化学股份有限公司（以下简称"公司"）分别于 2024 年 9 月 25 日和 26 日收到中国证券登记结算有限责任公司上海分公司（以下简称"中 登公司"）短信通知，公司持股 5%以上股东股份发生变化，通过中登公司系统查 询，获悉公司股东云南水务投资股份有限公司（以下简称"云南水务"）于 2024 年 9 月 24 日新增司法冻结 2,500,000 股，于 2024 年 9 月 25 日解除司法冻结并 完成过户 8,075,745 股。 ●过户完成后，云南水务持有公司股份数量为 167,350,891 股，剩余累计被 冻结股份 5,500,000 股，全部为限售流通股，占其所持股份比例为 3.29%，占公 司总股本比例为 0.63%。 ● 云南水务不是公司的控股 ...

浙江钱江生物化学股份有限公司 关于孙公司为其子公司提供担保的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 ●重要内容提示: 被担保人名称：勃利县金河湾污水处理有限公司（以下简称"勃利县金河湾"）、 北安市银水湾污水处理有限公司（以下简称"北安市银水湾"）、孙吴县银水湾 污水处理有限公司（以下简称"孙吴县银水湾"）、北安市长青金河湾污水处理 有限公司（以下简称"长青金河湾"）、明水银水湾污水处理有限公司（以下简 称"明水银水湾"），以上 5 家公司合称"本次被担保对象"。 ●本次担保金额及已实际为其提供的担保余额 本次担保金额为 1,700 万元，已实际为其提供的担保余额 7,310 万元（包含 本次担保） ●本次担保是否有反担保：否 ●对外担保逾期的累计数量：0 元 一、 担保情况概述 证券代码：600796 股票简称：钱江生化 编号：临 2024—037 浙江海云环保有限公司（以下简称"海云环保"）为浙江钱江生物化学股份 有限公司（以下简称"公司"）的全资子公司，海云环保持有哈尔滨北方环保工 程有限公司（以下简 ...

证券代码：600796 股票简称：钱江生化 编号：临 2024—036 浙江钱江生物化学股份有限公司 关于持股 5%以上股东所持部分公司股份被司法拍卖 的进展公告 1 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： ●本次被司法拍卖的标的为云南水务投资股份有限公司（以下简称"云南水 务"）所持有的浙江钱江生物化学股份有限公司（以下简称"公司"或"钱江生 化"）冻结的限售流通股 8,075,745 股，占公司总股本的 0.93%，占其所持股份 比例为 4.60%。 ●截止本公告披露日，拍卖网拍阶段已经结束，上述股份以人民币 2,883.836 万元的价格成交。后续涉及缴款、法院执行法定程序、股权变更过户 等环节，仍存在一定的不确定性，最终结果以广东省揭阳市榕城区人民法院（以 下简称"法院"）出具的法院裁定为准。 ● 云南水务不是公司的控股股东、实际控制人，上述股份被司法拍卖，不 会导致公司实际控制权发生变更，不会对公司的生产经营、公司治理产生重大影 响。 2024 年 8 月 16 日，公司披露了《关于持股 ...

证券代码：600796 证券简称：钱江生化 浙江钱江生物化学股份有限公司 投资者关系活动记录表 | --- | --- | --- | |-------------------------|------------------------------------------------------------|--------------------------------------------------------| | | | | | 投资者关系活动 | □特定对象调研 | □分析师会议 | | 类别 | □媒体采访 | √业绩说明会 | | | □新闻发布会 | □路演活动 | | | □现场参观 | □其他 | | 参与单位名称及 人员姓名 | 线上参与公司 2024 | 年半年度业绩说明会的投资者 | | 时间 | 2024 年 9 月 3 日 | 10:00 至 11:00 | | | https://roadshow.sseinfo.com/） | | | 上市公司接待人 员姓名 | 董事长、总经理：孙玉超 独立董事：王利达 董事会秘书：陆萍燕 | | | | | | | | 财务总监：马月 ...

Financial Performance - The company's operating revenue for the first half of 2024 was ¥862,661,241.69, a decrease of 0.55% compared to ¥867,389,372.66 in the same period last year[12]. - The net profit attributable to shareholders for the first half of 2024 was ¥82,251,281.43, down 2.62% from ¥84,467,995.97 in the previous year[12]. - The net profit attributable to shareholders after deducting non-recurring gains and losses increased by 6.33% to ¥80,354,997.56 from ¥75,573,760.67 year-on-year[12]. - Basic earnings per share decreased by 10.00% to CNY 0.09 compared to the same period last year[14]. - Diluted earnings per share also decreased by 10.00% to CNY 0.09 compared to the same period last year[14]. - The total comprehensive income for the first half of 2024 was 82,251,281.43 RMB, a decrease of 16,637,084.75 RMB compared to the previous period[167]. - The total profit for the first half of 2024 was CNY 88,413,345.28, a decrease of 11.1% from CNY 99,413,388.70 in the first half of 2023[157]. Cash Flow and Investments - The net cash flow from operating activities was ¥7,571,423.36, representing an increase of 28.58% compared to ¥5,888,482.78 in the previous year[13]. - The company's investment activities generated a net cash outflow of approximately CNY 447.88 million, an increase of 468.52% year-on-year[48]. - Cash inflow from financing activities reached ¥960.40 million, a substantial increase from ¥124.80 million in the previous year, marking a growth of 669.5%[163]. - The company's cash and cash equivalents at the end of the period amounted to ¥975.80 million, up from ¥630.88 million at the end of the previous year, representing a growth of 54.5%[163]. Assets and Liabilities - The total assets at the end of the reporting period were ¥7,553,439,303.20, an increase of 9.93% from ¥6,871,323,089.13 at the end of the previous year[13]. - The total liabilities were CNY 692,764,379.35, up from CNY 108,829,265.45 at the end of 2023[154]. - The company's total non-current assets amounted to approximately 4.99 billion RMB, up from 4.54 billion RMB, reflecting an increase of 9.83%[150]. - The company's total equity at the end of the reporting period was ¥2,928,029,965.49[178]. Environmental and Regulatory Compliance - The company is classified as a key pollutant discharge unit, adhering to strict environmental standards for wastewater and air emissions[66][67]. - The company has established a comprehensive environmental management system to control pollution and ensure compliance with regulations[59][66]. - The company has implemented strict control measures for toxic and harmful substance emissions, reporting annually to the ecological environment authorities[91]. - The company has established a soil pollution risk control standard, ensuring compliance with GB36600-2018 for soil monitoring factors[91]. Research and Development - The company focuses on R&D for bio-pesticides, with key products including plant growth regulators and various insecticides, targeting major agricultural regions in China[28]. - The company has established a post-doctoral innovation workstation and collaborates with external research institutions to enhance product development and technology improvement[29]. - The company is investing in the construction of a molecular biology platform to improve research and development capabilities and optimize product quality[40]. Market and Industry Trends - The environmental protection industry in China had a market revenue of approximately CNY 2.22 trillion in 2022, growing by about 1.9% from 2021[15]. - The biopesticide market is expected to grow at a compound annual growth rate of 17.1%, reaching 21.5% of the total pesticide market by 2027[18]. - The company faces challenges such as insufficient industry chain extension and intense market competition in its ecological environmental business[17]. Corporate Governance and Shareholder Relations - The company has not proposed any profit distribution plan or capital reserve transfer to share capital for this reporting period[3]. - The company has committed to maintaining independence from its controlling shareholders and related parties to protect the interests of minority shareholders[112]. - There are no significant lawsuits or arbitration matters reported during the reporting period[114]. Financial Management and Debt - The company’s interest-bearing debt increased from 0.00 billion RMB at the beginning of the period to 6.00 billion RMB at the end, representing a 100% year-on-year change[144]. - The consolidated interest-bearing debt rose from 19.47 billion RMB to 25.61 billion RMB, reflecting a year-on-year increase of 31.54%[145]. - The company has established a special account for the management of raised funds, ensuring good execution of the fund usage[142]. Strategic Initiatives - The company aims to enhance its market presence in both domestic and international water supply and drainage sectors[21]. - The company is committed to expanding its franchise projects into municipal sanitation and hazardous waste management sectors to ensure long-term stable growth[37]. - The company has successfully raised 600 million yuan through the issuance of green corporate bonds for project construction[44].

证券代码：600796 证券简称：钱江生化 公告编号：临 2024-035 浙江钱江生物化学股份有限公司 关于召开 2024 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： https://roadshow.sseinfo.com/） 浙江钱江生物化学股份有限公司（以下简称"公司"）已于 2024 年 8 月 27 日发布公司 2024 年半年度报告，为便于广大投资者更全面 深入地了解公司 2024 年半年度经营成果、财务状况，公司计划于 2024 年 09 月 03 日 上午 10:00-11:00 举行 2024 年半年度业绩说明会， 就投资者关心的问题进行交流。 一、 说明会类型 会议召开时间：2024 年 09 月 03 日(星期二) 上午 10:00-11:00 会议召开地点：上海证券交易所上证路演中心（网址： 会议召开方式：上证路演中心网络互动 投资者可于 2024 年 08 月 27 日(星期二) 至 09 月 02 日(星期 一)16:00 前登录上证路演中心网站首页点 ...